Related Experiment Video
Updated: Jun 4, 2025

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
Structure-activity relationship of synthesized glucans from Ganoderma lucidum with in vitro hypoglycemic activity
Liu Yang1, Jia Huang2, Ni Huang3
1State Key Laboratory of Phytochemistry and Plant Resources in West China, Yunnan Key Laboratory of Natural Medicinal Chemistry, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650201, China.
Abstract:
The synthetic polysaccharides, which have precise structure, can be used to design new drugs by comparing structure-activity relationships (SAR). Improved protein stability may be due to the interaction between the polysaccharides and protein, which includes covalent and noncovalent interactions. It is critical to investigate the SAR of polysaccharides with a precise structure from the perspective of protein stability. Glucans-insulin interaction may be a useful stratagy to solve this problem. This study reports the SAR of the synthesized glucan GLSWA-1 and its substructures 2-4 on insulin secretion and discusses its mechanism. The results showed that although GLSWA-1 and its substructures 2-4 bind insulin to varying degrees, compound 2 improves insulin secretion in a dose-dependent manner. Further research found that compound 2 maintains the thermal stability of insulin better than GLSWA-1 through stronger hydrogen bonding, and molecular dynamics simulations demonstrated that compound 2 can form a "groove-binding model" with insulin. This study considerably improves the research on the SAR of glucan based on insulin thermostability and indicates that compound 2, its linear structure, appropriate chain flexibility ((1 → 6)-glucoside bonds), low molecular weight, and smaller steric hindrance is a potential hypoglycemic agent.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Hypoglycemia and Glucagon
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones

